Regeneron REGN moved higher on the Tuesday session to top at $337 from the $313 open. The stock faded towards the later part of the session.
In a mid-day note on Tuesday, Deutsche Bank reiterates its buy rating, and raised their price target from $410 to $425.
Deutsche Bank mentions the solid earnings results and the beat on expectations for Regeneron's highest grossing drug, Eylea:
“Eylea 2Q sales in the US were $415M vs. $410M consensus. In 1Q'14 the company did $359M in Eylea Us sales. Since 1Q'14 sales were impacted by weather and inventory this growth was expected in 2Q. The co reaffirmed 2014 full year guidance at $1.7-$1.8B. We note that this guidance means ~$925-$1025M sales in 2H'14 vs. ~$775M sales in 1H'14. Per our calc this suggests ~$50-$150M incremental sales in DME in 2H'14.”
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in